8
Global Reach and Impact
Focus on efficiency, standardised manufacturing
processes and integrated supply chain
Moreover, in February 2021, CSL joined the Pharmaceutical
Supply Chain Initiative (PSCI) to leverage a growing industry
membership base and its extensive supply chain expertise.
The PSCI is a global non-profit business membership
organisation based in the US with a vision to establish and
promote responsible practices that will continuously improve
social, health, safety and environmental sustainable outcomes
for supply chains. As a result of our membership and in
support of embedding PSCI’s principles, in June 2021, CSL
developed its first Third Party Code of Conduct. Complementing
CSL’s Code of Responsible Business Practice, the new Third
Party Code makes explicitly clear our expectations for the
conduct of CSL business by its third parties/suppliers.
CSL’s end-to-end operations organisation has a critical role
to play in helping to deliver on our 2030 strategy, so we can
continue saving people’s lives and improving public health
across the globe. Over the last year, we have been evolving
our end-to-end operations to build on its strengths and
create an engaged and inclusive culture that consistently
delivers top-tier results in the key areas of safety, quality,
reliability and innovation.
To meet the global demand for CSL’s lifesaving medicines,
we are focused on driving a global mindset and creating
an end-to-end operation organisation that is modern and
scalable, from plasma collection through to our patients.
Over the last year, we have made enhancements to our
supply chain and manufacturing capabilities, introducing
concepts such as reliability rooms, to give us greater visibility
and control across our network. End-to-end operations is
also working more closely than ever before with key internal
partners such as commercial operations and R&D, and
using more predictive thinking and modelling to anticipate
potential challenges, minimise risk and identify solutions.
During the COVID-19 pandemic, increased global demand
put immense pressure on worldwide supply chains but
we managed to mitigate this risk and keep our sites fully
operational. This was achieved by working cross-functionally
and with our external strategic supply partners to identify
and implement alternative materials that created approved
alternative sources of supply and concurrently de-risked the
future on some critical materials.
In a multi-year investment, the first serialisation of Seqirus
products was supplied for the 2019/20 influenza season
in the US and Europe. Serialisation is where a unique serial
number is printed on each pack of vaccines. It helps to
combat counterfeit products and provides the basis for full
track and trace of our vaccines in the future. Seqirus’ southern
hemisphere products are also now serialisation-capable.
For CSL Plasma, the collection of vital human-derived plasma
for the development of lifesaving products is industry-leading
and a critical part of CSL’s supply chain. With careful localised
management of operations, including donor remuneration,
CSL Plasma facilities minimise donor time via integrated
donor management systems including electronic biometric
identification and check-in, streamlined floor layouts and
an operational excellence approach driving a cohesive culture
of efficiency and teamwork. Throughout the COVID-19
pandemic, CSL Plasma has utilised a wide variety of measures
to ensure the safety of donors and employees and address
challenges such as the need for social distancing, stay-at-
home orders and mandated capacity reductions.
Modern Slavery Statement
In February 2021, CSL’s first,
Board-approved, public
Modern Slavery Statement
under new Australian
CSL’s Statement on Modern Slavery
1 July 2019 to 30 June 2020
About our Statement
laws was published by the
Australian regulator. While
we are aware that the fight
against forced labour and
other egregious forms
of modern slavery will
take time, planning and
collaboration to identify,
remedy and ultimately
Towards meeting the expectations of disclosure requirements in
a number of jurisdictions, this Statement
1
on Modern Slavery (the Statement) describes the risks of modern slavery in our business, the steps that
we have taken to identify, manage and mitigate those risks in our operations and supply chains, and how
we evaluate the effectiveness of our responses.
The Statement is
a joint statement in relation to the reporting period 1 July 2019 and 30 June 2020
prepared by and for CSL Limited and also for the reporting entities CSL Behring (Australia) Pty Ltd and
Seqirus (Australia) Pty Ltd.
For the purposes of this Statement, ‘CSL’, ‘we’, ‘us’ and ‘our’ collectively refers to CSL Limited, CSL Behring,
Secure and reliable supply
Ca lSs Lo Pd le
a
s
s
c
m
ri ba e
a
s
n
p
d
r aS ce
t
q
i ci re
u
s
st(h
a
a
n
t
d
a irne c cl uo dm
e
m
s
a
ol nl r te ol e Cv Sa nL ’ ts r
o
e
t
p
h
o
e
r
r
tic
n
o
g
nte
r
no tl li et i de se fn
o
t
ri tt i he iss a
S
nt ad t Ce mS L e- mn t a) . nT ah
g
i se Sd t aj ot ie
n
m
t
ve
e
n
nt ture
operations (together with CSL, referred to as the ‘Group’ or the ‘CSL Group’).
Modern slavery is used to describe serious forms of exploitation where coercion, threats or deception
ae rx
e
plu
si te
dtito
o
nei xn pc ll ou idt ev :i ct rt ai mf fi
s
c ak ni n
d
gui nn d
e
r
m
s oi nn es ; os rl a dv ee pr yr i; v
e
e rt vh i et um d eo ;f f tohr ec ier dfr
ee
dr roi am g. eT ; yf po re
s
o
fl
s
e
br oi o
ur s; debt
o
a
p
e
r
s
m
a
c
e
d
a
u
bondage; deceptive recruiting for labour or services; and the worst forms of child labour.
During the financial year, the External Supply Integration
function accelerated targeted partnering with world-class
contract manufacturers, analytical services and logistics
providers. The partnering efforts were focused on reducing
risk and increasing supply reliability. A number of ongoing
partnering initiatives will be operational in 2022/23 in support
of the 2030 strategy by delivering growth, reliability and
innovation through investments made by the chosen partners.
Organisational structure
CSL Limited is the parent of the CSL Group and is headquartered in Melbourne, Australia. It is listed on the
Australian Securities Exchange (ASX) and is constituent of the S&P/ASX 20 index.
a
Ct h
S
L
s ies t
a
hla
e
a tdr ie
n
gt hg al o
b
ma lo
b
pi ho it l ei ac ha nn do l oi mg ym
c
o
me p
a
n
y
c wi e int hc i ea s
d
ay ns aw me li lc
ps o
r
at cf oc li ino e os ftl oi f ep - rs
a
v
ei nn gt i mn fl
e
d
ei cn i zn
e. sS, i in
n
c
lu
d
i nr gs tart
o
t
a
e
u
n
d
e
fi
,
a
v
e
v
u
a
c
e
o
u
in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL
–
through
our two businesses, CSL Behring and eqirus provides life-saving products to more than 100 countries and
S
2
–
employs 27,009 people in 39 countries. Our unique combination of commercial strength, research and
development focus and operational excellence enables us to identify, develop and deliver innovations
so our patients and global communities can live life to the fullest.
1
The Statement has been prepared for purposes of the Modern Slavery Act 2018 (Cth) (Act), United Kingdom Modern Slavery Act 2015
2
As at 30 June 2020.
CSL’s Statement on Modern Slavery
–
1
July 2019 to 30 June 2020
1
prevent, inroads have been made. Through CSL’s
Supply Chain Integrity Council and new third party risk
management process we have increased our efforts to
better screen and identify modern slavery risks. You can
read more on CSL’s response in our 2020 Statement
on CSL.com (Our Company > Corporate Responsibility >
Key Publications).
In June 2021, CSL deployed an improved end-to-end process
for the assessment of third parties across a number of risk
domains, including the implementation of a new risk
management tool. The improved enterprise-wide third party
risk management process and new platform will centralise
the onboarding of third parties based on new critical third-
party criteria, delivering significant benefits to our
stakeholders including:
•
proactive and comprehensive identification of supplier
risks, delivering against our 2030 objective of efficiency
and reliable supply, by identifying and remediating risk
in our supply chain;
•
•
•
•
standardised risk and performance scoring across suppliers,
thus improving compliance and audit readiness;
ability to report and revise supplier risk metrics more
frequently and more proactively;
defined criteria to consistently identify critical third
parties; and
automated integration between existing enterprise systems
to enable efficiencies and improved data management.
3
8
CSL Limited Annual Report 2020/21